{
  "id": "biomarker-compliance-by-method",
  "display_name": "Biomarker Testing by Method",
  "cohort": "Biomarker Testing, by Method (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "NGS panel testing utilized in only 38% of eligible cases, far below the 65% benchmark. Increasing NGS utilization represents a $245,000 annual opportunity in improved therapy matching.",
  "chart": {
    "type": "bar",
    "unit": "method",
    "data": [
      { "name": "IHC", "value": 92, "gap": 2, "highlight": false },
      { "name": "FISH", "value": 85, "gap": -5, "highlight": false },
      { "name": "PCR", "value": 78, "gap": -12, "highlight": false },
      { "name": "Liquid Biopsy", "value": 42, "gap": -18, "highlight": true },
      { "name": "NGS Panel", "value": 38, "gap": -27, "highlight": true },
      { "name": "RNA-seq", "value": 22, "gap": -43, "highlight": true }
    ],
    "benchmark": 65,
    "nccn_target": 80
  },
  "financial_impact": {
    "annual_opportunity": "$245,000/year",
    "math": "$245,000/year = 27% testing gap (NGS) × 65 patients × $14,000 improved therapy matching"
  },
  "clinical_impact": {
    "description": "Comprehensive NGS panel testing improves therapy matching and patient outcomes.",
    "metrics": [
      {
        "type": "TM",
        "value": "+54%",
        "description": "Improved therapy matching rate with NGS vs. single-gene testing"
      },
      {
        "type": "OS",
        "value": "+6.7 months",
        "description": "Overall survival benefit with NGS-guided therapy selection"
      },
      {
        "type": "CT",
        "value": "+42%",
        "description": "Increased clinical trial eligibility identification"
      },
      {
        "type": "TT",
        "value": "-35%",
        "description": "Reduced need for repeat testing"
      },
      {
        "type": "Hosp",
        "value": "-28%",
        "description": "Reduced hospitalization rates"
      }
    ],
    "quantitative": "+54% therapy matching"
  },
  "peer_comparison": {
    "description": "Leading oncology practices utilize NGS panel testing in 75% of eligible cases compared to your 38%, resulting in better outcomes.",
    "peer_benchmark": 75,
    "financial_impact": {
      "annual_opportunity": "$335,000/year",
      "math": "$335,000/year = 37% gap to peer benchmark × 65 patients × $14,000 improved care value"
    },
    "action_steps": [
      {
        "text": "Develop NGS panel ordering pathway in EMR",
        "icon": "document"
      },
      {
        "text": "Create decision support tool for molecular testing",
        "icon": "lightbulb"
      },
      {
        "text": "Implement automatic trigger for NGS at diagnosis for advanced disease",
        "icon": "cog"
      },
      {
        "text": "Establish molecular tumor board program",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 91,
  "action_steps": [
    {
      "text": "Develop NGS-first protocol for advanced solid tumors",
      "icon": "document"
    },
    {
      "text": "Implement liquid biopsy program for tissue-limited cases",
      "icon": "flask"
    },
    {
      "text": "Create provider education program on comprehensive testing",
      "icon": "users"
    },
    {
      "text": "Establish NGS test utilization tracking dashboard",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Evaluate use of rapid RNA-seq for quick therapy matching",
      "icon": "clock"
    },
    {
      "text": "Consider in-house NGS capability vs. send-out testing",
      "icon": "building"
    }
  ],
  "drilldowns": [
    {
      "label": "By Cancer Type",
      "cohort": "Biomarker Testing by Cancer Type",
      "jsonFile": "biomarker-compliance-by-cancer.json",
      "drilldownLevel": 1
    },
    {
      "label": "By Provider",
      "cohort": "Biomarker Testing by Provider",
      "jsonFile": "biomarker-compliance-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "Turnaround Time",
      "cohort": "Biomarker Testing Turnaround Time",
      "jsonFile": "biomarker-compliance-tat.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 